Qube Research & Technologies (QRT)
MRNA icon

Qube Research & Technologies (QRT)’s Moderna MRNA Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.2M Sell
231,200
-148,900
-39% -$7.7M 0.02% 1010
2026
Q1 		$19.3M Sell
380,100
-419,800
-52% -$19.6M 0.02% 899
2025
Q4 		$23.6M Sell
799,900
-80,000
-9% -$2.17M 0.02% 822
2025
Q3 		$22.7M Sell
879,900
-810,400
-48% -$22.6M 0.02% 833
2025
Q2 		$46.6M Buy
1,690,300
+525,000
+45% +$13.8M 0.05% 499
2025
Q1 		$33M Buy
1,165,300
+82,600
+8% +$2.93M 0.04% 542
2024
Q4 		$45M Buy
1,082,700
+828,400
+326% +$39.6M 0.06% 412
2024
Q3 		$17M Buy
254,300
+164,900
+184% +$15.1M 0.03% 760
2024
Q2 		$10.6M Buy
89,400
+60,900
+214% +$7.71M 0.02% 887
2024
Q1 		$3.04M Sell
28,500
-77,200
-73% -$7.78M ﹤0.01% 1516
2023
Q4 		$10.5M Sell
105,700
-20,500
-16% -$1.72M 0.02% 715
2023
Q3 		$13M Buy
+126,200
New +$14.1M 0.03% 541

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Qube Research & Technologies (QRT)'s MRNA Position: Q2 2026 in Review

Qube Research & Technologies (QRT) increased its Moderna (MRNA) stake by 29% in Q2 2026, buying an estimated $10.7M and bringing the position to 907,157 shares worth $63.5M. The position accounts for 0.06% of the portfolio, ranked #416.

Qube Research & Technologies (QRT) first reported a position in MRNA in Q1 2020 and has held it in 14 quarters since. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Qube Research & Technologies (QRT) held 907,157 shares of Moderna worth $63.5M as of Q2 2026.
  • Qube Research & Technologies (QRT) bought 206,465 Moderna shares in Q2 2026, an estimated $10.7M.
  • Moderna made up 0.06% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #416 holding.
  • Qube Research & Technologies (QRT) first reported a position in Moderna in Q1 2020 and has held it in 14 quarters since.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.